|
|
Development and Evaluation of High Throughput Functional Assay Methods for hERG Potassium Channel
Weimin Tang
Department of Profiling and High Throughput Screening, Aventis Pharmaceuticals, Bridgewater, NJ
Jiesheng Kang
Department of Safety Pharmacology, Aventis Pharmaceuticals, Bridgewater, NJ
Xiaying Wu
Department of Profiling and High Throughput Screening, Aventis Pharmaceuticals, Bridgewater, NJ
David Rampe
Department of Safety Pharmacology, Aventis Pharmaceuticals, Bridgewater, NJ
Lin Wang
Department of Safety Pharmacology, Aventis Pharmaceuticals, Bridgewater, NJ
Hong Shen
Department of Analytical Chemistry, Aventis Pharmaceuticals, Bridgewater, NJ
Zhuyin Li
Department of Profiling and High Throughput Screening, Aventis Pharmaceuticals, Bridgewater, NJ
Damien Dunnington
Axiom Biotechnology, San Diego, CA
Tina Garyantes
Department of Profiling and High Throughput Screening, Aventis Pharmaceuticals, Bridgewater, NJ
Three functional hERG channel assay methods have been developed and evaluated. The methods were tested against five known hERG channel inhibitors: dofetilide, terfenadine (Seldane), sertindole (Serdolect), astemizole (Hismanal), and cisapride (Propulsid). The DiBAC4(3)-based assays were found to be the most economical but had high false-hit rates as a result of the interaction of dye with the test compounds. The membrane potential dye assay had fewer color-quenching problems but was expensive and still gave false hits. The nonradioactive Rb+ efflux assay was the most sensitive of all the assays evaluated and had the lowest false-hit rate.
Journal of Biomolecular Screening, Vol. 6, No. 5,
325-331 (2001)
DOI: 10.1177/108705710100600506

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. J. Perrin, P. W. Kuchel, T. J. Campbell, and J. I. Vandenberg
Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-a-go-go-Related Gene Channels
Mol. Pharmacol.,
November 1, 2008;
74(5):
1443 - 1452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. D. Guth
Preclinical Cardiovascular Risk Assessment in Modern Drug Development
Toxicol. Sci.,
May 1, 2007;
97(1):
4 - 20.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Dorn, F. Hermann, A. Ebneth, H. Bothmann, G. Trube, K. Christensen, and C. Apfel
Evaluation of a High-Throughput Fluorescence Assay Method for hERG Potassium Channel Inhibition
J Biomol Screen,
June 1, 2005;
10(4):
339 - 347.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Wolff, B. Fuks, and P. Chatelain
Comparative Study of Membrane Potential-Sensitive Fluorescent Probes and their Use in Ion Channel Screening Assays
J Biomol Screen,
October 1, 2003;
8(5):
533 - 543.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Falconer, F. Smith, S. Surah-Narwal, G. Congrave, Z. Liu, P. Hayter, G. Ciaramella, W. Keighley, P. Haddock, G. Waldron, et al.
High-Throughput Screening for Ion Channel Modulators
J Biomol Screen,
October 1, 2002;
7(5):
460 - 465.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. F. Baxter, M. Kirk, A. F. Garcia, A. Raimondi, M. H. Holmqvist, K. K. Flint, D. Bojanic, P. S. Distefano, R. Curtis, and Y. Xie
A Novel Membrane Potential-Sensitive Fluorescent Dye Improves Cell-Based Assays for Ion Channels
J Biomol Screen,
February 1, 2002;
7(1):
79 - 85.
[Abstract]
[PDF]
|
 |
|
|
|